Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KAND567 in Healthy Subjects
NCT06030375Phase 1Completed
- Sponsor
- Kancera
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing KAND567 with Placebo (2 arms). Primary endpoints: Safety and tolerability measured by adverse events, Safety and tolerability measured by vital signs and 7 more. Started Feb 2020; status: completed.
02
Drugs
rugocrixan
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06030375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06030375.